Mallinckrodt's subsidiary, SpecGx, will offer refunds to covered entities for over 30 years of overcharges.

SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges

June 3, 2025 Bella Czajkowski, National Correspondent Views

SpecGx, a generic subsidiary of Mallinckrodt Pharmaceuticals, will refund 340B covered entities that purchased addiction treatment medication Methadose for above [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

SpecGx to Offer Covered Entities Refunds for a Record 30-Plus Years of 340B Overcharges

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Bella Czajkowski

Staff Email

Site Footer Live